GlassScriptPhysician profile
Mark D Stoeckel
NPI 1689671042
$7,655.64
in general payments reported to CMS, 2019-2025
46 companies · $1,584 in 2025
The $1,584 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,843 · 2020: $46.27 · 2021: $427 · 2022: $920 · 2023: $1,510 · 2024: $1,325 · 2025: $1,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,337 · Education: $82.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,337.24 |
| Education | $82.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,114.93 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,083.27 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $746.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $499.01 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $491.86 | 2019-2025 | |
| Lilly USA, LLC | $302.57 | 2019-2025 | Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $300.62 | 2021-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $287.98 | 2022-2025 | |
| Amgen INC. | $281.70 | 2019-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.98 | 2019-2025 | Jardiance |
| Abbott Laboratories | $221.91 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Astellas Pharma US INC | $190.53 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $185.71 | 2019-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.88 | 2019-2024 | Xifaxan |
| Exact Sciences Corporation | $114.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Stoeckel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.